121 related articles for article (PubMed ID: 35478055)
1. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
Reyes DK; Trock BJ; Tran PT; Pavlovich CP; Deville C; Allaf ME; Greco SC; Song DY; Bivalacqua TJ; Han M; Partin AW; Sartor AO; Rowe SP; Pienta KJ
Med Oncol; 2022 Apr; 39(5):63. PubMed ID: 35478055
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.
Reyes DK; Rowe SP; Schaeffer EM; Allaf ME; Ross AE; Pavlovich CP; Deville C; Tran PT; Pienta KJ
Med Oncol; 2020 Jun; 37(7):60. PubMed ID: 32524295
[TBL] [Abstract][Full Text] [Related]
3. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Parikh NR; Huiza C; Patel JS; Tsai S; Kalpage N; Thein M; Pitcher S; Lee SP; Inouye WS; Jordan ML; Sanati H; Jafari L; Bennett CJ; Gin GE; Kishan AU; Reiter RE; Lewis M; Sadeghi A; Aronson WJ; Garraway IP; Rettig MB; Nickols NG
BMC Cancer; 2019 Apr; 19(1):291. PubMed ID: 30935383
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
8. Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial.
Guttilla A; Bortolus R; Giannarini G; Ghadjar P; Zattoni F; Gnech M; Palumbo V; Valent F; Garbeglio A; Zattoni F
Radiat Oncol; 2014 Jan; 9():24. PubMed ID: 24423462
[TBL] [Abstract][Full Text] [Related]
9. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Sheikhbahaei S; Reyes DK; Rowe SP; Pienta KJ
Prostate; 2021 Feb; 81(2):127-134. PubMed ID: 33259087
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
11. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
Koontz BF; Hoffman KE; Halabi S; Healy P; Anand M; George DJ; Harrison MR; Zhang T; Berry WR; Corn PG; Lee WR; Armstrong AJ
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1271-1278. PubMed ID: 33259932
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
13. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
17. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.
Gandaglia G; Fossati N; Stabile A; Bandini M; Rigatti P; Montorsi F; Briganti A
Eur Urol; 2017 Aug; 72(2):289-292. PubMed ID: 27574820
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
20. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
